Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

BACKGROUND: Cladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing schedule is for 2 courses given a year apart, which has been sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Maltby, Vicki E, Lea, Rodney A, Monif, Mastura, Fabis-Pedrini, Marzena J, Buzzard, Katherine, Kalincik, Tomas, Kermode, Allan G, Taylor, Bruce, Hodgkinson, Suzanne, McCombe, Pamela, Butzkueven, Helmut, Barnett, Michael, Lechner-Scott, Jeannette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2021
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564661/
https://www.ncbi.nlm.nih.gov/pubmed/34665152
http://dx.doi.org/10.2196/24969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8564661/
https://www.ncbi.nlm.nih.gov/pubmed/34665152
http://dx.doi.org/10.2196/24969

Ejemplares similares